As accumulating evidence has shown that constitutive activation of STAT5 by abnormal JAK activity is a major cause of cancer and hematological malignancies, several JAK inhibitors have been used to treat STAT5-associated diseases [74,75]. This evidence concerns the gene STAT5B and cancer.